US20100144899A1 - Method for preparing nano-emulsions - Google Patents
Method for preparing nano-emulsions Download PDFInfo
- Publication number
- US20100144899A1 US20100144899A1 US12/527,371 US52737108A US2010144899A1 US 20100144899 A1 US20100144899 A1 US 20100144899A1 US 52737108 A US52737108 A US 52737108A US 2010144899 A1 US2010144899 A1 US 2010144899A1
- Authority
- US
- United States
- Prior art keywords
- weight
- fatty acids
- nano
- phase
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000012071 phase Substances 0.000 claims abstract description 87
- 150000002632 lipids Chemical class 0.000 claims abstract description 41
- 239000008346 aqueous phase Substances 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 50
- 239000004064 cosurfactant Substances 0.000 claims description 33
- 239000003921 oil Substances 0.000 claims description 29
- 235000019198 oils Nutrition 0.000 claims description 28
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 26
- 229930195729 fatty acid Natural products 0.000 claims description 26
- 239000000194 fatty acid Substances 0.000 claims description 26
- 239000000839 emulsion Substances 0.000 claims description 25
- 150000004665 fatty acids Chemical class 0.000 claims description 24
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- -1 C12 fatty acids Chemical class 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 238000000527 sonication Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000944 linseed oil Substances 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 235000021388 linseed oil Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 claims description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical class CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 238000009472 formulation Methods 0.000 description 24
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 22
- 239000000787 lecithin Substances 0.000 description 15
- 235000010445 lecithin Nutrition 0.000 description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 13
- 229940067606 lecithin Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 125000005456 glyceride group Chemical group 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000575 polymersome Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021060 food property Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0078—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion microemulsion, nanoemulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/14—Derivatives of phosphoric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Definitions
- the present invention relates to a method for preparing nano-emulsions.
- Nano-emulsions also known as mini-emulsions, ultrafine emulsions or even submicron emulsions, are emulsions in which the dispersed phase has an average diameter generally of between 10 and 200 nm.
- an emulsion is a mixture of two immiscible liquid substances consisting of a continuous phase and a dispersed phase. One substance is dispersed in the second substance (continuous phase) in the form of small droplets (dispersed phase). The mixture remains stable due to the action of amphiphilic molecules, termed “emulsifying” or “surfactant”, which position themselves at the interface between the two phases.
- Emulsions are metastable supramolecular structures. These structures are shown in FIG. 3B and are distinct from polymersomes and micelles.
- Polymersomes (the family containing liposomes) are vesicles having an average diameter varying from tens to thousands of nanometres. These vesicles are composed of one or more bilayers of surfactants which allow the intravesicular medium to be separated from the external medium, the two media being of the same type, most often aqueous ( FIG. 3A ).
- Micelles consist of aggregates of self-assembled surfactants measuring a few nanometres in diameter. Surfactants organise themselves in such a way as to orient the hydrophilic part thereof towards the outside (the solvent) and the hydrophobic chains thereof towards the centre of the micelle (see FIG. 3C ).
- solubilise the surfactants in a solvent, which is subsequently evaporated so as to form a film of surfactants.
- the water or aqueous solution is subsequently added and the mixture is sonicated in order to disperse the film of surfactants.
- the oil is subsequently dispersed in the solution of liposomes obtained.
- the diphasic solution obtained is sonicated once again or treated with a microfluidiser to produce the nano-emulsion (Vyas, T. K.; Shahiwala, A.; Amiji, M.
- the main object of the present invention is to propose a method for preparing nano-emulsions which overcomes one or more of the above drawbacks.
- the object of the present invention is to propose a simple method which gives access to nano-emulsions with a low-diameter dispersed phase.
- Another object of the invention is to propose a method for preparing nano-emulsions which makes it possible to control the size of the dispersed phase and/or the physicochemical properties of the interface.
- the object is achieved by a method of preparing a nano-emulsion in which at least one low-solubility surfactant, in particular a phospholipid, is solubilised in the oily phase due to the presence of a solubilising lipid.
- the present invention therefore relates to a method for preparing nano-emulsions comprising at least one aqueous continuous phase and at least one oily dispersed phase, comprising the steps of:
- the nano-emulsion prepared using the method according to the invention comprises an oily phase and an aqueous phase.
- the oily phase comprises at least one amphiphilic lipid and at least one solubilising lipid.
- At least one amphiphilic lipid in the composition as a surfactant.
- amphiphilic nature of the surfactant or surfactants causes the droplets of oil to stabilise within the aqueous continuous phase.
- at least two surfactants are used to prepare a nano-emulsion.
- the surfactant may also have other effects in the intended application of the nano-emulsion.
- the oily phase comprises at least one amphiphilic lipid.
- amphiphilic lipids may be of natural or synthetic origin. They are preferably selected from phospholipids; cholesterol; lysolipids; sphingomyelins; tocopherols; glucolipids; stearylamines and cardiolipins.
- Lecithin is the preferred amphiphilic lipid.
- all or part of the amphiphilic lipid may have a reactive function, such as a maleimide, thiol, amine, ester, oxyamine or aldehyde group.
- a reactive function such as a maleimide, thiol, amine, ester, oxyamine or aldehyde group.
- the oily phase will comprise 1 to 99% by weight, preferably 5 to 75% by weight and in particular 20 to 60% by weight amphiphilic lipid.
- the solubilising lipid is a lipid having a sufficient affinity for the amphiphilic liquid to allow it to be solubilised.
- the amphiphilic lipid is a phospholipid
- possible solubilising lipids are, in particular, glycerol derivatives, especially glycerides obtained by esterifying glycerol with fatty acids.
- the solubilising lipid used is advantageously selected in dependence on the amphiphilic lipid used. It will generally have a close chemical structure so as to bring about the desired solubilisation. It may be an oil or a wax.
- the preferred solubilising lipids are glycerides of fatty acids, in particular of saturated fatty acids, and in particular of saturated fatty acids comprising 8 to 18 carbon atoms, even more preferably 12 to 18 carbon atoms.
- saturated fatty acid glycerides comprising 0% to 20% by weight C8 fatty acids, 0% to 20% by weight C10 fatty acids, 10% to 70% by weight C12 fatty acids, 5% to 30% by weight C14 fatty acids, 5% to 30% by weight C16 fatty acids and 5% to 30% by weight C18 fatty acids are involved.
- the type N Suppocire® glycerides are obtained by direct esterification of fatty acids and glycerol. These are semi-synthetic glycerides of C8 to C18 saturated fatty acids, of which the quali-quantitative composition is shown in the table below.
- the amount of solubilising lipid may vary widely as a function of the type and amount of amphiphilic lipid present in the oily phase.
- the oily phase will comprise 1 to 99% by weight, preferably 5 to 75% by weight and in particular 10 to 50% by weight solubilising lipid.
- the oily phase further comprises one or more other oils.
- oils used in the method according to the invention preferably have a hydrophilic-lipophilic balance (HLB) of less than 8 and even more preferably of between 3 and 6.
- HLB hydrophilic-lipophilic balance
- the oils are used without any chemical or physical modification in advance of the formation of the emulsion.
- the oils may be selected from biocompatible oils, in particular from oils of natural (plant or animal) or synthetic origin.
- Oils of this type include, in particular, oils of natural plant origin, including in particular soybean, linseed, palm, peanut, olive, grape seed and sunflower oils; and synthetic oils, including in particular triglycerides, diglycerides and monoglycerides. These oils may be in their natural form, refined or interesterified.
- the preferred oils are soybean oil and linseed oil.
- the oily phase comprises 1 to 70% by weight, preferably 2 to 50% by weight and in particular 5 to 30% by weight of oil.
- oily phase may also contain other additives, such as colourings, stabilisers, preservatives, fluorophores or pharmacological active ingredients in an appropriate amount.
- additives such as colourings, stabilisers, preservatives, fluorophores or pharmacological active ingredients in an appropriate amount.
- the different oily constituents are initially mixed to prepare an oily premix for the dispersed phase of the emulsion.
- the mixing may optionally be facilitated by placing one of the constituents or the complete mixture in solution in an appropriate organic solvent, followed by evaporating the solvent, leaving a homogeneous oily premix for the dispersed phase.
- the premix at a temperature at which all of the ingredients are liquid.
- the aqueous phase used in the method according to the invention preferably consists of water and/or a buffer, such as a phosphate buffer, for example PBS (“phosphate buffer saline”) or another saline solution, in particular sodium chloride.
- a buffer such as a phosphate buffer, for example PBS (“phosphate buffer saline”) or another saline solution, in particular sodium chloride.
- it optionally comprises other ingredients, preferably including a cosurfactant.
- cosurfactants which may be used in emulsions according to the present invention are preferably water-soluble surfactants.
- the water-soluble surfactants preferably comprise at least one chain composed of ethylene oxide units (PEO or PEG) or ethylene oxide and propylene oxide units.
- PEO ethylene oxide units
- PEG ethylene oxide and propylene oxide units.
- the number of units in the chain varies between 2 and 500.
- co-surfactants include, in particular, the conjugated compounds polyethyleneglycol/phosphatidylethanolamine (PEG-PE), fatty acid and polyethylene glycol ethers such as the products sold under the Brij® trade names (for example Brij® 35, 58, 78 or 98) by ICI Americas Inc., fatty acid and polyethylene glycol esters such as the products sold under the Myrj® trade names by ICI Americas Inc.
- PEG-PE polyethyleneglycol/phosphatidylethanolamine
- fatty acid and polyethylene glycol ethers such as the products sold under the Brij® trade names (for example Brij® 35, 58, 78 or 98) by ICI Americas Inc.
- fatty acid and polyethylene glycol esters such as the products sold under the Myrj® trade names by ICI Americas Inc.
- the aqueous phase preferably comprises 0 to 50% by weight, preferably 1 to 30% by weight and in particular 5 to 20% by weight of a water-soluble cosurfactant.
- the continuous phase also comprises a thickening agent such as a glycerol, a saccharide, oligosaccharide or polysaccharide, a gum or even a protein, preferably glycerol.
- a thickening agent such as a glycerol, a saccharide, oligosaccharide or polysaccharide, a gum or even a protein, preferably glycerol.
- the aqueous phase advantageously comprises 0 to 50% by weight, preferably 1 to 30% by weight and in particular 5 to 20% by weight of a thickening agent.
- the aqueous phase may further comprise other additives such as colourings, stabilisers and preservatives in appropriate amounts.
- the aqueous premix for the continuous phase of the emulsion may be prepared by simply mixing the different constituents with the selected aqueous medium.
- the nano-emulsion is prepared by dispersing appropriate amounts of oily phase and aqueous phase under the effect of a shear force.
- the proportion of oily phase and aqueous phase is highly variable.
- the nano-emulsions will be prepared with 1 to 50%, preferably 5 to 40%, and in particular 10 to 30% by weight oily phase and 50 to 99%, preferably 60 to 95% and in particular 70 to 90% by weight aqueous phase.
- the oily phase is subsequently dispersed in the aqueous phase in a liquid state. If one of the phases solidifies at room temperature, it is preferable to make the mixture with the two phases heated to a temperature greater than or equal to the fusion temperature.
- the emulsification under shear force effect is preferably produced using a sonicator or a microfluidiser.
- the aqueous phase and then the oily phase are introduced into an appropriate cylindrical receptacle in the desired proportions and the sonicator is dipped into the medium and switched on for long enough to obtain a nano-emulsion, usually a few minutes.
- the emulsion Before conditioning, the emulsion may be diluted and/or sterilised, for example by filtration.
- the filtration step also makes it possible to eliminate any aggregates which might have formed during preparation of the emulsion.
- FIG. 1 is a schematic drawing of the production of nano-emulsions by ultrasound according to the prior art
- FIG. 2 is a comparison drawing of the production of nano-emulsions by ultrasound according to a preferred embodiment of the invention
- FIG. 3 is a schematic drawing of the structure of a nano-emulsion (b) in terms of the micellar systems (c) and the polymersomes (a), the structures all having water as the continuous phase;
- FIG. 4 shows the size distribution, weighted by volume, of a nano-emulsion prepared according to example 1, the percentage by volume being shown as a function of the size in nm;
- FIG. 5 shows the average diameter of the dispersed phase of the nano-emulsions according to example 1 ( ⁇ ) and example 2 as a function of the total amount of surfactants at an even surfactant/cosurfactant molar ratio;
- FIG. 6 shows the average diameter of the dispersed phase of the nano-emulsions according to example 1 ( ⁇ ) and example 3 as a function of the amount of surfactants and cosurfactants;
- FIG. 7 shows the progression over time of the average diameter of nano-emulsions prepared according to example 1.
- a premix was prepared consisting of 0.125 g of soybean oil (Sigma-Aldrich), 0.375 g of semi-synthetic glycerides sold under the trade name Suppocire® NC (Gattefossé) and 0.350 g of soy lecithin (enriched with 75% phosphatidylcholine) sold by Lipo ⁇ d under the trade name Lipo ⁇ d® S75.
- the continuous phase was prepared by mixing 0.125 g of glycerol, 0.55 g of polyoxyethylene stearate with 50 moles ethylene oxide sold under the trade name Myrj® 53 by ICI Americas Inc. and phosphate buffer solution, PBS, to make the mixture up to 4.150 g. This solution was kept hot (50-60° C.) before emulsification.
- the aqueous solution was subsequently added to the oil/lecithin mixture. Then, the diphasic solution was brought into contact with an AV505® sonicator provided with a conical probe measuring 3 mm in diameter (Sonics, Newtown) which was dipped about 1 cm into the solution. The solution was sonicated for 5 minutes with the sonicator set to 30% of the maximum power, with the following pulse sequence: 10 seconds sonication/30 seconds rest. During sonication, the solution was kept at 40° C.
- the average diameter of the dispersed phase of the prepared emulsion was determined by dynamic light diffusion (Zetasizer nano ZS, Malvern Instrument)
- the dispersed phase of the nano-emulsions thus obtained had an average diameter of 35 nm ( FIG. 4 ).
- Table 1 summarises the composition of the formulation of the nano-emulsion obtained.
- FIG. 7 shows the stability over time of nano-emulsions prepared according to example 1.
- Example 1 was then reproduced but the surfactants/cosurfactants ratio was varied, whilst the molar amount of surfactants was kept constant however.
- the size of the dispersed phase of the emulsions obtained is given as a function of the concentration of lecithin and Myrj® 53, the nominal formulation being represented by a square. The data are shown in the diagram of FIG. 6 .
- the size of the droplets decreases with the amount of surfactant, but also with the amount of cosurfactant. It may further be noted that the effect of the cosurfactant seems to be considerably more significant in this respect.
- the surfactant/cosurfactant ratio thus also makes it possible to control the diameter of the dispersed phase by simultaneously altering the composition of the interface of the emulsion.
- example 1 In order to study the effect of the length of the hydrophilic chains of the cosurfactant, the formulation of example 1 was reproduced, but Myrj® 53 was replaced with cosurfactants carrying polyoxyethylene chains of a different length.
- the length of the hydrophilic chains in the cosurfactant has some influence on the average diameter of the dispersed phase of the emulsion obtained for the formulations of example 4. Specifically, the average diameter of the dispersed phase of the emulsion decreases considerably as the length of the chains increases.
- nano-emulsion of example 4 with a cosurfactant having very long chains proved to be unstable.
- the very low diameter of the dispersed phase (15.3 nm) also suggests the presence of a micellar solution rather than a nano-emulsion.
- example 5 which is equimolar in surfactants, results in nano-emulsions in which the diameter of the dispersed phase remains close to 30 nm. It is therefore possible in this case to alter the length of the hydrophilic chains without significantly affecting the diameter of the particles.
- the dispersed phase is composed of a mixture of 75% by weight solubilising lipid (Suppocire® NC) and 25% by weight soybean oil.
- the solubilising lipid is rich in saturated medium-chain fatty acids, whilst the soybean oil is rich in ⁇ 6-type unsaturated acids (C18:2) and the linseed oil is rich in ⁇ 3-type unsaturated acids (C18:3).
- Nano-emulsions were therefore prepared of which the dispersed phase was composed of pure solubilising lipid or of a mixture of solubilising lipid and soybean oil or linseed oil.
- the respective composition of the nano-emulsions in solubilising lipid and oil is shown in percent by weight in table 8 below.
- example 5 the formulation of example 5 is maintained, this formulation having the advantage of reducing the amount of lecithin by comparison with the formulation of example 1, thus allowing the amount of solubilising lipid to be reduced whilst allowing good solubilisation of the lecithin.
- the formulation of the nano-emulsions excluding the oily phase is summarised in table 7 below.
- composition of the dispersed phase of the emulsion can be altered without changing the diameter thereof, thus making it possible to alter the solubilisation characteristics without affecting the diameter of the dispersed phase of the nano-emulsions.
- the method described above therefore makes it possible to obtain stable, homogeneous nano-emulsions quickly and easily.
- the method further makes it possible to control the average diameter of the dispersed phase, the interface and/or the dispersed phase of the nano-emulsions via the concentration and the type of surfactants used, as described above.
Abstract
- (i) preparing the oily phase comprising at least one amphiphilic lipid and at least one solubilising lipid;
- (ii) dispersing the oily phase in an aqueous phase under the effect of sufficient shear force to form a nano-emulsion; and
- (iii) recovering the nano-emulsion thus formed.
Description
- The present invention relates to a method for preparing nano-emulsions.
- Nano-emulsions, also known as mini-emulsions, ultrafine emulsions or even submicron emulsions, are emulsions in which the dispersed phase has an average diameter generally of between 10 and 200 nm.
- It will be remembered that an emulsion is a mixture of two immiscible liquid substances consisting of a continuous phase and a dispersed phase. One substance is dispersed in the second substance (continuous phase) in the form of small droplets (dispersed phase). The mixture remains stable due to the action of amphiphilic molecules, termed “emulsifying” or “surfactant”, which position themselves at the interface between the two phases. Emulsions are metastable supramolecular structures. These structures are shown in
FIG. 3B and are distinct from polymersomes and micelles. - Polymersomes (the family containing liposomes) are vesicles having an average diameter varying from tens to thousands of nanometres. These vesicles are composed of one or more bilayers of surfactants which allow the intravesicular medium to be separated from the external medium, the two media being of the same type, most often aqueous (
FIG. 3A ). - Micelles consist of aggregates of self-assembled surfactants measuring a few nanometres in diameter. Surfactants organise themselves in such a way as to orient the hydrophilic part thereof towards the outside (the solvent) and the hydrophobic chains thereof towards the centre of the micelle (see
FIG. 3C ). - A number of methods for preparing oil-in-water nano-emulsions are known.
- A method has thus been proposed in which the surfactants are solubilised in the continuous phase, i.e. the water (Jafari, S. M.; He, Y.; Bhandari, B., Production of sub-micron emulsions by ultrasound and microfluidization techniques. Journal of Food engineering 2007, 82, (4), 478-488 and Jafari, S. M.; He, Y.; Bhandari, B., Nano-emulsion production by sonication and microfluidization—A comparison. International Journal of Food Properties 2006, 9, (3), 475-485 and Mason, T. G.; Wilking, J. N.; Meleson, K.; Chang, C. B.; Graves, S. M., Nanoemulsions: formation, structure, and physical properties. Journal of Physics: Condensed Matter 2006, 18, (41), R635-R666).
- However, a large number of surfactants, in particular phospholipids, do not dissolve easily in the aqueous phase and in the oily phase. It is therefore hard to incorporate into one of the phases the amount of surfactant necessary to obtain nano-emulsions with a low-diameter dispersed phase.
- In order to be able to solubilise a larger amount of surfactant, it has been proposed to solubilise the surfactants in a solvent, which is subsequently evaporated so as to form a film of surfactants. The water or aqueous solution is subsequently added and the mixture is sonicated in order to disperse the film of surfactants. The oil is subsequently dispersed in the solution of liposomes obtained. The diphasic solution obtained is sonicated once again or treated with a microfluidiser to produce the nano-emulsion (Vyas, T. K.; Shahiwala, A.; Amiji, M. M., Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. International Journal of Pharmaceutics 2008, 347 (1-2), 93-101) and US 2005/0079131. However, this method is long and requires a plurality of sonication steps. Moreover, the presence of residual liposomes in the nano-emulsion cannot be excluded.
- The main object of the present invention is to propose a method for preparing nano-emulsions which overcomes one or more of the above drawbacks.
- In particular, the object of the present invention is to propose a simple method which gives access to nano-emulsions with a low-diameter dispersed phase.
- Another object of the invention is to propose a method for preparing nano-emulsions which makes it possible to control the size of the dispersed phase and/or the physicochemical properties of the interface.
- The object is achieved by a method of preparing a nano-emulsion in which at least one low-solubility surfactant, in particular a phospholipid, is solubilised in the oily phase due to the presence of a solubilising lipid.
- The present invention therefore relates to a method for preparing nano-emulsions comprising at least one aqueous continuous phase and at least one oily dispersed phase, comprising the steps of:
- (i) preparing the oily phase comprising at least one amphiphilic lipid and at least one solubilising lipid;
(ii) dispersing the oily phase in an aqueous phase under the effect of sufficient shear force to form a nano-emulsion; and
(iii) recovering the nano-emulsion thus formed. - The method according to the present invention has the following advantages in particular:
-
- it includes only a single step of sonication;
- it allows significant amounts of surfactants to be dissolved and thus allows the preparation of nano-emulsions with a low-diameter dispersed phase;
- it is quick, because the aqueous phase has a low proportion of surfactant and is therefore less viscous and can be emulsified quickly; and
- it avoids the formation of liposomes and thus allows access to a homogeneous nano-emulsion.
- Within the meaning of the present invention:
-
- the term “droplet” encompasses droplets of liquid oil as such, as well as the solid particles from oil-in-water emulsions in which the oil used is a crystallisable oil. In the latter case, the term “solid emulsion” is also often used.
- the term “lipid” refers to small molecules consisting primarily of carbon, hydrogen and oxygen and having a density lower than that of the water. The lipids can be in a solid state, as in waxes, or liquid, as in oils.
- the term “amphiphilic” refers to species having a hydrophilic group and a hydrophobic group. Amphiphilic compounds have surfactant properties, i.e. they alter the surface tension between two surfaces.
- the term “phospholipid” refers to lipids having a phosphate group, in particular phosphoglycerides. Most often, phospholipids comprise a hydrophilic end formed by the optionally substituted phosphate group and two hydrophobic ends formed by fatty acid chains. Particular phospholipids include phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and sphingomyelin.
- the term “lecithin” refers to phosphatidylcholine, i.e. a lipid formed from a choline, a phosphate, a glycerol and two fatty acids. More broadly, it includes phospholipids extracted from living sources, of plant or animal origin, as long as they primarily consist of phosphatidylcholine. These lecithins generally consist of mixtures of lecithins carrying different fatty acids.
- within the meaning of the invention, the term “nano-emulsion” refers to an emulsion in which the dispersed phase has an average diameter of between 10 and 200 nm, preferably between 10 and 150 nm and in particular between 10 and 80 nm.
- The nano-emulsion prepared using the method according to the invention comprises an oily phase and an aqueous phase.
- The oily phase comprises at least one amphiphilic lipid and at least one solubilising lipid.
- To form a stable nano-emulsion, it is generally necessary to include at least one amphiphilic lipid in the composition as a surfactant.
- The amphiphilic nature of the surfactant or surfactants causes the droplets of oil to stabilise within the aqueous continuous phase. Usually, at least two surfactants are used to prepare a nano-emulsion. The surfactant may also have other effects in the intended application of the nano-emulsion.
- According to the invention, the oily phase comprises at least one amphiphilic lipid.
- These amphiphilic lipids may be of natural or synthetic origin. They are preferably selected from phospholipids; cholesterol; lysolipids; sphingomyelins; tocopherols; glucolipids; stearylamines and cardiolipins.
- Lecithin is the preferred amphiphilic lipid.
- In one specific embodiment, all or part of the amphiphilic lipid may have a reactive function, such as a maleimide, thiol, amine, ester, oxyamine or aldehyde group. This variant allows functional compounds to graft at the interface. The reactive amphiphilic lipid is incorporated into the layer formed at the interface stabilising the dispersed phase, where it is liable to couple to a reactive compound present in the aqueous phase.
- Generally, the oily phase will comprise 1 to 99% by weight, preferably 5 to 75% by weight and in particular 20 to 60% by weight amphiphilic lipid.
- The solubilising lipid is a lipid having a sufficient affinity for the amphiphilic liquid to allow it to be solubilised. In the case where the amphiphilic lipid is a phospholipid, possible solubilising lipids are, in particular, glycerol derivatives, especially glycerides obtained by esterifying glycerol with fatty acids.
- The solubilising lipid used is advantageously selected in dependence on the amphiphilic lipid used. It will generally have a close chemical structure so as to bring about the desired solubilisation. It may be an oil or a wax.
- The preferred solubilising lipids, in particular for phospholipids, are glycerides of fatty acids, in particular of saturated fatty acids, and in particular of saturated fatty acids comprising 8 to 18 carbon atoms, even more preferably 12 to 18 carbon atoms.
- Preferably, saturated fatty acid glycerides comprising 0% to 20% by weight C8 fatty acids, 0% to 20% by weight C10 fatty acids, 10% to 70% by weight C12 fatty acids, 5% to 30% by weight C14 fatty acids, 5% to 30% by weight C16 fatty acids and 5% to 30% by weight C18 fatty acids are involved.
- The semi-synthetic glyceride mixtures sold by Gattefossé under the trade name Suppocire® NC, which are solid at room temperature, are particularly preferred. The type N Suppocire® glycerides are obtained by direct esterification of fatty acids and glycerol. These are semi-synthetic glycerides of C8 to C18 saturated fatty acids, of which the quali-quantitative composition is shown in the table below.
- The amount of solubilising lipid may vary widely as a function of the type and amount of amphiphilic lipid present in the oily phase.
- Generally, the oily phase will comprise 1 to 99% by weight, preferably 5 to 75% by weight and in particular 10 to 50% by weight solubilising lipid.
-
TABLE Fatty acid composition of Suppocire NC ® from Gattefossé Chain length [% by weight] C8 0.1 to 0.9 C10 0.1 to 0.9 C12 25 to 50 C14 10 to 24.9 C16 10 to 24.9 C18 10 to 24.9 - Preferably, the oily phase further comprises one or more other oils.
- The oils used in the method according to the invention preferably have a hydrophilic-lipophilic balance (HLB) of less than 8 and even more preferably of between 3 and 6.
- Advantageously, the oils are used without any chemical or physical modification in advance of the formation of the emulsion.
- In the proposed applications, the oils may be selected from biocompatible oils, in particular from oils of natural (plant or animal) or synthetic origin.
- Oils of this type include, in particular, oils of natural plant origin, including in particular soybean, linseed, palm, peanut, olive, grape seed and sunflower oils; and synthetic oils, including in particular triglycerides, diglycerides and monoglycerides. These oils may be in their natural form, refined or interesterified.
- The preferred oils are soybean oil and linseed oil.
- Generally, the oily phase comprises 1 to 70% by weight, preferably 2 to 50% by weight and in particular 5 to 30% by weight of oil.
- Naturally, the oily phase may also contain other additives, such as colourings, stabilisers, preservatives, fluorophores or pharmacological active ingredients in an appropriate amount.
- In the method according to the invention, the different oily constituents are initially mixed to prepare an oily premix for the dispersed phase of the emulsion. The mixing may optionally be facilitated by placing one of the constituents or the complete mixture in solution in an appropriate organic solvent, followed by evaporating the solvent, leaving a homogeneous oily premix for the dispersed phase.
- Furthermore, it is preferred to produce the premix at a temperature at which all of the ingredients are liquid.
- The aqueous phase used in the method according to the invention preferably consists of water and/or a buffer, such as a phosphate buffer, for example PBS (“phosphate buffer saline”) or another saline solution, in particular sodium chloride.
- Moreover, it optionally comprises other ingredients, preferably including a cosurfactant.
- The cosurfactants which may be used in emulsions according to the present invention are preferably water-soluble surfactants.
- The water-soluble surfactants preferably comprise at least one chain composed of ethylene oxide units (PEO or PEG) or ethylene oxide and propylene oxide units. Preferably, the number of units in the chain varies between 2 and 500.
- Examples of co-surfactants include, in particular, the conjugated compounds polyethyleneglycol/phosphatidylethanolamine (PEG-PE), fatty acid and polyethylene glycol ethers such as the products sold under the Brij® trade names (for
example Brij® 35, 58, 78 or 98) by ICI Americas Inc., fatty acid and polyethylene glycol esters such as the products sold under the Myrj® trade names by ICI Americas Inc. (forexample Myrj® 45, 52, 53 or 59) and block copolymers of ethylene oxide and propylene oxide such as the products sold under the Pluronic® trade names by BASF AG (for example Pluronic® F68, F127, L64, L61, 10R4, 17R2, 17R4, 25R2 or 25R4) or the products sold under the Synperonic® trade name by Unichema Chemie BV (for example Synperonic® PE/F68, PE/L61 or PE/L64). - The aqueous phase preferably comprises 0 to 50% by weight, preferably 1 to 30% by weight and in particular 5 to 20% by weight of a water-soluble cosurfactant.
- In a preferred embodiment, the continuous phase also comprises a thickening agent such as a glycerol, a saccharide, oligosaccharide or polysaccharide, a gum or even a protein, preferably glycerol. In fact, the use of a continuous phase of a higher viscosity facilitates emulsification and thus allows the sonication time to be reduced.
- The aqueous phase advantageously comprises 0 to 50% by weight, preferably 1 to 30% by weight and in particular 5 to 20% by weight of a thickening agent.
- Naturally, the aqueous phase may further comprise other additives such as colourings, stabilisers and preservatives in appropriate amounts.
- The aqueous premix for the continuous phase of the emulsion may be prepared by simply mixing the different constituents with the selected aqueous medium.
- In the method according to the invention, the nano-emulsion is prepared by dispersing appropriate amounts of oily phase and aqueous phase under the effect of a shear force.
- The proportion of oily phase and aqueous phase is highly variable. However, usually, the nano-emulsions will be prepared with 1 to 50%, preferably 5 to 40%, and in particular 10 to 30% by weight oily phase and 50 to 99%, preferably 60 to 95% and in particular 70 to 90% by weight aqueous phase.
- Advantageously, the oily phase is subsequently dispersed in the aqueous phase in a liquid state. If one of the phases solidifies at room temperature, it is preferable to make the mixture with the two phases heated to a temperature greater than or equal to the fusion temperature.
- The emulsification under shear force effect is preferably produced using a sonicator or a microfluidiser. Preferably, the aqueous phase and then the oily phase are introduced into an appropriate cylindrical receptacle in the desired proportions and the sonicator is dipped into the medium and switched on for long enough to obtain a nano-emulsion, usually a few minutes.
- This produces a homogeneous nano-emulsion in which the average diameter of the oil droplets is greater than 10 nm and less than 200 nm.
- Before conditioning, the emulsion may be diluted and/or sterilised, for example by filtration. The filtration step also makes it possible to eliminate any aggregates which might have formed during preparation of the emulsion.
- The invention will be explained in greater detail by means of the examples, given by way of illustration, and the appended figures, in which:
-
FIG. 1 is a schematic drawing of the production of nano-emulsions by ultrasound according to the prior art; -
FIG. 2 is a comparison drawing of the production of nano-emulsions by ultrasound according to a preferred embodiment of the invention; -
FIG. 3 is a schematic drawing of the structure of a nano-emulsion (b) in terms of the micellar systems (c) and the polymersomes (a), the structures all having water as the continuous phase; -
FIG. 4 shows the size distribution, weighted by volume, of a nano-emulsion prepared according to example 1, the percentage by volume being shown as a function of the size in nm; -
FIG. 5 shows the average diameter of the dispersed phase of the nano-emulsions according to example 1 (▪) and example 2 as a function of the total amount of surfactants at an even surfactant/cosurfactant molar ratio; -
FIG. 6 shows the average diameter of the dispersed phase of the nano-emulsions according to example 1 (▪) and example 3 as a function of the amount of surfactants and cosurfactants; and -
FIG. 7 shows the progression over time of the average diameter of nano-emulsions prepared according to example 1. - In an appropriate receptacle, a premix was prepared consisting of 0.125 g of soybean oil (Sigma-Aldrich), 0.375 g of semi-synthetic glycerides sold under the trade name Suppocire® NC (Gattefossé) and 0.350 g of soy lecithin (enriched with 75% phosphatidylcholine) sold by Lipoïd under the trade name Lipoïd® S75.
- These compounds were dissolved in chloroform, then the solution was evaporated at low pressure and dried at 50° C. so as to obtain a premix in the form of a viscous oil which solidifies as it cools. The mixture obtained was heated to 50-60° C. so as to keep it liquid for emulsification.
- The continuous phase was prepared by mixing 0.125 g of glycerol, 0.55 g of polyoxyethylene stearate with 50 moles ethylene oxide sold under the trade name Myrj® 53 by ICI Americas Inc. and phosphate buffer solution, PBS, to make the mixture up to 4.150 g. This solution was kept hot (50-60° C.) before emulsification.
- The aqueous solution was subsequently added to the oil/lecithin mixture. Then, the diphasic solution was brought into contact with an AV505® sonicator provided with a conical probe measuring 3 mm in diameter (Sonics, Newtown) which was dipped about 1 cm into the solution. The solution was sonicated for 5 minutes with the sonicator set to 30% of the maximum power, with the following pulse sequence: 10 seconds sonication/30 seconds rest. During sonication, the solution was kept at 40° C.
- The average diameter of the dispersed phase of the prepared emulsion was determined by dynamic light diffusion (Zetasizer nano ZS, Malvern Instrument)
- The dispersed phase of the nano-emulsions thus obtained had an average diameter of 35 nm (
FIG. 4 ). Table 1 summarises the composition of the formulation of the nano-emulsion obtained.FIG. 7 shows the stability over time of nano-emulsions prepared according to example 1. -
TABLE 1 formulation of the nano-emulsion of example 1 Example 1 Mass [mg] % by weight [mmol] Dispersed phase Soybean oil 125 2.5 Suppocire 375 7.5 Surfactants Lecithin 350 7 0.467 Myrj 53 550 11 0.233 Aqueous phase Glycerol 125 2.5 Buffer solution 3475 69.5 Total 5000 100 - In order to study the effect of surfactants on the formulation of example 1, said example was reproduced while varying the amount of lecithin and Myrj 53 but keeping the molar ratio between them [lecithin/(lecithin+Myrj® 53)] constant at a value of 0.67. The amount and the composition of the dispersed phase were unchanged as compared with the formulation of example 1. The amount of buffer solution was altered as a result to obtain 5 g of solution.
- In examples 2A and 2B, where there is a large amount of cosurfactant, glycerol was replaced with buffer solution because the solution was sufficiently viscous. Table 2 summarises the concentrations used for the different formulations, prepared as stated in example 1.
-
TABLE 2 formulation of the emulsions of examples 2A to 2K Surfactant Cosurfactant Total Ex- (lecithin) (Myrj ® 53) amount of Average am- % by % by surfactant diameter ple Mass [mg] weight Mass [mg] weight [mmol] [mm] 1 350 7 550 11 0.7 36.6 2A 420 8.4 660 13.2 0.84 35.1 2B 385 7.7 605 12.1 0.77 34.2 2C 315 6.3 495 9.9 0.63 37.4 2D 280 5.6 440 8.8 0.56 40.3 2E 245 4.9 385 7.7 0.49 45.7 2F 210 4.2 330 6.6 0.42 72.7 2G 175 3.5 275 5.5 0.35 92.9 2H 140 2.8 220 4.4 0.28 127 2I 105 2.1 165 3.3 0.21 170 2J 70 1.4 110 2.2 0.14 177 2K 35 0.7 55 1.1 0.07 272 - It is found that the average diameter of the dispersed phase of the nano-emulsions obtained decreases as the total amount of surfactants increases (see
FIG. 5 ). The formulation of example 1 is shown by a square inFIG. 5 . - It is therefore possible to control the size of the dispersed phase of the nano-emulsion by adjusting the amount of surfactants. However, two different patterns can be distinguished: below 0.5 mmol of surfactants, the average diameter varies rapidly with the amount of surfactants, whereas above this concentration, the average diameter does not change much. Formulations comprising more than 0.5 mmol of surfactants therefore seem more stable, given that a slight variation in the amount of surfactant only has a small effect on the eventual size of the dispersed phase of the nano-emulsions.
- Example 1 was then reproduced but the surfactants/cosurfactants ratio was varied, whilst the molar amount of surfactants was kept constant however.
- In examples 3A to 3F, where there is a large amount of cosurfactant, glycerol was replaced with buffer solution because the solution was sufficiently viscous. Table 3 summarises the concentrations used for the different formulations, prepared as stated in example 1.
-
Surfactant (lecithin) Cosurfactant Average % by (Myrj ® 53) diameter Example Mass [mg] weight Mass [mg] % by weight [mm] 1 350 7.0 550 11 34.3 3A 516 10.3 0 0 215 3B 387 7.7 428 9 48.8 3C 258 5.2 856 17 30.6 3D 172 3.4 1142 23 27.4 3E 129 2.6 1284 26 27.5 3F 0 0.0 1712 34 26.1 - The size of the dispersed phase of the emulsions obtained is given as a function of the concentration of lecithin and Myrj® 53, the nominal formulation being represented by a square. The data are shown in the diagram of
FIG. 6 . - It is found that the size of the droplets decreases with the amount of surfactant, but also with the amount of cosurfactant. It may further be noted that the effect of the cosurfactant seems to be considerably more significant in this respect.
- The surfactant/cosurfactant ratio thus also makes it possible to control the diameter of the dispersed phase by simultaneously altering the composition of the interface of the emulsion.
- In order to study the effect of the length of the hydrophilic chains of the cosurfactant, the formulation of example 1 was reproduced, but Myrj® 53 was replaced with cosurfactants carrying polyoxyethylene chains of a different length.
- The following cosurfactants were tested: Tween® 80,
Myrj® 45, Myrj® 49 and Myrj® 59. Table 4 below summarises the properties of these cosurfactants. - The cosurfactant in the formulation of example 1 was replaced with the same amount in moles, i.e. 0.233 mmol.
-
TABLE 4 properties of the polyethoxylated cosurfactants Polyethoxylated Number of polyoxyethylene cosurfactant (POE) units Molecular weight (g/mol) Tween ® 80 20 1310 Myrj ® 458 636 Myrj ® 49 20 1164 Myrj ® 53 50 2484 Myrj ® 59 100 4684 - The study of the effect of the length of the hydrophilic chains of the cosurfactants was corroborated with a second series of experiments performed as in example 4, but based on a formulation in which the surfactant and the cosurfactant are present in an equimolar amount (0.344 mmol).
- The results in terms of the average diameter of the dispersed phase are summarised for examples 4 and 5 in table 5 below.
-
TABLE 5 average diameter of the dispersed phase of the emulsions according to examples 4 and 5 Cosurfactant Example 4 [nm] Example 5 [nm] Tween ® 80 65.5 28.2 Myrj ® 45182 — Myrj ® 49 132 31.4 Myrj ® 53 34.7 29.5 Myrj ® 59 15.3 37.7 - It was found that the length of the hydrophilic chains in the cosurfactant has some influence on the average diameter of the dispersed phase of the emulsion obtained for the formulations of example 4. Specifically, the average diameter of the dispersed phase of the emulsion decreases considerably as the length of the chains increases.
- However, it should be noted that the nano-emulsion of example 4 with a cosurfactant having very long chains (Myrj® 59) proved to be unstable. The very low diameter of the dispersed phase (15.3 nm) also suggests the presence of a micellar solution rather than a nano-emulsion.
- On the other hand, the formulation of example 5, which is equimolar in surfactants, results in nano-emulsions in which the diameter of the dispersed phase remains close to 30 nm. It is therefore possible in this case to alter the length of the hydrophilic chains without significantly affecting the diameter of the particles.
- Finally, the effect of the composition of the oily phase on the average diameter of the dispersed phase was studied by varying the type and proportion of oil and solubilising lipid.
- In the formulation of example 1, the dispersed phase is composed of a mixture of 75% by weight solubilising lipid (Suppocire® NC) and 25% by weight soybean oil. The solubilising lipid is rich in saturated medium-chain fatty acids, whilst the soybean oil is rich in ω6-type unsaturated acids (C18:2) and the linseed oil is rich in ω3-type unsaturated acids (C18:3).
- Nano-emulsions were therefore prepared of which the dispersed phase was composed of pure solubilising lipid or of a mixture of solubilising lipid and soybean oil or linseed oil. The respective composition of the nano-emulsions in solubilising lipid and oil is shown in percent by weight in table 8 below.
- Otherwise, the formulation of example 5 is maintained, this formulation having the advantage of reducing the amount of lecithin by comparison with the formulation of example 1, thus allowing the amount of solubilising lipid to be reduced whilst allowing good solubilisation of the lecithin. The formulation of the nano-emulsions excluding the oily phase is summarised in table 7 below.
-
TABLE 7 formulation of the nano-emulsions of example 6 Mass in mg % [mmol] Dispersed phase Total oil 500 10 Surfactants Lecithin 258 5 0.344 Myrj ® 53 827.5 16.55 0.344 Aqueous phase Glycerol 125 2.5 Buffer solution 3289.5 65.95 - Table 8 below summarises the average diameter of the dispersed phase in the nano-emulsions obtained with the composition shown
-
TABLE 8 change in the average diameter as a function of the composition of the oily phase Suppocire ® NC Soybean oil Linseed oil Average Example % by weight % by weight % by weight diameter (d, nm) 6A 75 25 0 29 6B 50 50 0 30.4 6C 25 75 0 30.9 6D 100 0 0 29.2 6E 75 0 25 29 6F 50 0 50 28.3 6G 25 0 75 30 - These results show that the composition of the dispersed phase of the emulsion can be altered without changing the diameter thereof, thus making it possible to alter the solubilisation characteristics without affecting the diameter of the dispersed phase of the nano-emulsions.
- The method described above therefore makes it possible to obtain stable, homogeneous nano-emulsions quickly and easily. The method further makes it possible to control the average diameter of the dispersed phase, the interface and/or the dispersed phase of the nano-emulsions via the concentration and the type of surfactants used, as described above.
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2007/000269 WO2008102065A1 (en) | 2007-02-14 | 2007-02-14 | Fluorescent emulsions for optical imaging |
FRPCT/FR2007/000269 | 2007-02-14 | ||
PCT/FR2008/050249 WO2008104717A2 (en) | 2007-02-14 | 2008-02-14 | Method for preparing nano-emulsions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100144899A1 true US20100144899A1 (en) | 2010-06-10 |
Family
ID=38353357
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/527,314 Active 2030-07-30 US9072775B2 (en) | 2007-02-14 | 2008-02-14 | Fluorescent emulsions for optical imaging |
US12/527,371 Abandoned US20100144899A1 (en) | 2007-02-14 | 2008-02-14 | Method for preparing nano-emulsions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/527,314 Active 2030-07-30 US9072775B2 (en) | 2007-02-14 | 2008-02-14 | Fluorescent emulsions for optical imaging |
Country Status (6)
Country | Link |
---|---|
US (2) | US9072775B2 (en) |
EP (2) | EP2131869B1 (en) |
JP (2) | JP5620111B2 (en) |
ES (1) | ES2482090T3 (en) |
IL (2) | IL200115A (en) |
WO (3) | WO2008102065A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100303732A1 (en) * | 2007-09-14 | 2010-12-02 | Mivenion Gmbh | Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations |
US20110200532A1 (en) * | 2008-08-14 | 2011-08-18 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Fluorescent emulsion of indocyanine green |
CN102166270A (en) * | 2011-04-06 | 2011-08-31 | 西北农林科技大学 | Oil-in-water type dried orange peel oil nano-emulsion and preparation method thereof |
US20110274622A1 (en) * | 2008-08-14 | 2011-11-10 | Commissariat a L"energie atomique et aux energies alternatives | Nanocrystal Nano-Emulsion |
WO2013008083A1 (en) * | 2011-07-13 | 2013-01-17 | National Institute Of Pharmaceutical Education And Research (Niper) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen |
US20130251629A1 (en) * | 2010-02-17 | 2013-09-26 | Commissariat a l'energie atomique et aux energies alternatives PARIS FRANCE Nationality: French | Nanoemulsion for the delivery of at least two agents of interest |
CN104152138A (en) * | 2014-06-26 | 2014-11-19 | 苏州科技学院 | Weak light frequency upconversion o/w type microemulsion system |
US9707305B2 (en) | 2011-10-05 | 2017-07-18 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Formulas for diagnosing and treating hormone-dependent cancers and cancers of the organs responsible for steroid hormone synthesis |
US10092506B2 (en) | 2008-08-14 | 2018-10-09 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008102065A1 (en) | 2007-02-14 | 2008-08-28 | Commissariat A L'energie Atomique | Fluorescent emulsions for optical imaging |
FR2935001B1 (en) * | 2008-08-14 | 2011-12-30 | Commissariat Energie Atomique | FLUORESCENT EMULSION |
US8820832B2 (en) | 2011-11-22 | 2014-09-02 | Nissan North America, Inc. | Active head restraint with wiring pass-through |
FR2991196B1 (en) * | 2012-05-29 | 2014-06-27 | Capsum | TARGETING NANOPARTICLES FOR BIOLOGICAL APPLICATION |
FR2998899B1 (en) | 2012-11-30 | 2015-07-17 | Commissariat Energie Atomique | HIGH-THROUGH SCREENING METHOD FOR THE IDENTIFICATION OF BIOMARKERS, THERAPEUTIC TARGETS OR THERAPEUTIC AGENTS |
FR3022347B1 (en) * | 2014-06-17 | 2018-01-12 | Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris | BIOMIMETIC LIQUID PARTICLES, METHOD AND DEVICE FOR MEASURING FLOW CYTOMETRY |
US10175219B2 (en) * | 2014-07-28 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method to sort cells on the basis of radionuclide uptake |
FR3081350B1 (en) * | 2018-05-24 | 2020-08-28 | Paris Sciences Lettres Quartier Latin | COLLOIDAL PARTICLES HOMOGENEOUSLY FUNCTIONALIZED BY BIOMOLECULES |
US10486155B1 (en) | 2018-10-22 | 2019-11-26 | Klaris Corporation | Vacuum-loaded, droplet-generating microfluidic chips and related methods |
US10953404B1 (en) | 2020-04-24 | 2021-03-23 | Pattern Bioscience, Inc. | Apparatuses for contactless loading and imaging of microfluidic chips and related methods |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152923A (en) * | 1989-06-26 | 1992-10-06 | Hans Georg Weder | Process for the production of a nanoemulsion of oil particles in an aqueous phase |
US20020015721A1 (en) * | 1999-01-05 | 2002-02-07 | Jean-Thierry Simonnet | Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
US6541018B1 (en) * | 1998-12-17 | 2003-04-01 | L'oreal | Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
WO2006102768A1 (en) * | 2005-04-01 | 2006-10-05 | Alpharx Inc. | Colloidal solid lipid vehicle for pharmaceutical use |
US20060257493A1 (en) * | 2005-04-28 | 2006-11-16 | Amiji Mansoor M | Nanoparticulate delivery systems for treating multi-drug resistance |
US20070053988A1 (en) * | 2003-10-13 | 2007-03-08 | Audrey Royere | Monodispersed solid lipid particle compositions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78929A0 (en) * | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
ATE94057T1 (en) * | 1988-12-20 | 1993-09-15 | Medicontrol Corp | EMULSIONS DEHYDRATED BY HEAT. |
JP2785981B2 (en) * | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | Emulsion composition |
US5403575A (en) * | 1991-12-12 | 1995-04-04 | Hemagen/Pfc | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
JPH08506081A (en) * | 1993-02-12 | 1996-07-02 | ファーモス コーポレイション | Dry composition for the preparation of submicron emulsions |
CA2091152C (en) * | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
FR2721210B1 (en) * | 1994-06-17 | 1996-08-02 | Oreal | Cleaning composition containing lipid grains. |
EP0979103B1 (en) | 1997-04-29 | 2004-01-02 | Amersham Health AS | Light imaging contrast agents |
JP2001526650A (en) * | 1997-04-29 | 2001-12-18 | ニユコメド・イメージング・アクシエセルカペト | Optical contrast agent |
US5976502A (en) * | 1997-10-21 | 1999-11-02 | Gholam A. Peyman | Method of visualizing particles and blood cells containing a fluorescent lipophilic dye in the retina and choroid of the eye |
DE19852245A1 (en) * | 1998-11-12 | 2000-05-18 | Asat Ag Applied Science & Tech | 5-aminolevulinic acid nanoemulsion |
AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
EP1651276A4 (en) * | 2003-08-08 | 2009-05-06 | Barnes Jewish Hospital | Emulsion particles for imaging and therapy and methods of use thereof |
ITMI20050218A1 (en) * | 2005-02-15 | 2006-08-16 | Maycos Italiana Di Comini Miro | NANOEMULSIONS INCLUDING LIPOAMINO ACIDS MONOGLYCERIDES DIGLYCERIDES POLYGLYCERIDES OF FATTY ACIDS |
US20070148194A1 (en) * | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
WO2008102065A1 (en) | 2007-02-14 | 2008-08-28 | Commissariat A L'energie Atomique | Fluorescent emulsions for optical imaging |
-
2007
- 2007-02-14 WO PCT/FR2007/000269 patent/WO2008102065A1/en active Application Filing
-
2008
- 2008-02-14 WO PCT/FR2008/050249 patent/WO2008104717A2/en active Application Filing
- 2008-02-14 ES ES08762097.7T patent/ES2482090T3/en active Active
- 2008-02-14 JP JP2009549457A patent/JP5620111B2/en active Active
- 2008-02-14 EP EP08775556.7A patent/EP2131869B1/en active Active
- 2008-02-14 US US12/527,314 patent/US9072775B2/en active Active
- 2008-02-14 JP JP2009549444A patent/JP5837279B2/en active Active
- 2008-02-14 WO PCT/FR2008/000196 patent/WO2008125747A2/en active Application Filing
- 2008-02-14 EP EP08762097.7A patent/EP2129455B1/en active Active
- 2008-02-14 US US12/527,371 patent/US20100144899A1/en not_active Abandoned
-
2009
- 2009-07-28 IL IL200115A patent/IL200115A/en active IP Right Grant
- 2009-08-12 IL IL200351A patent/IL200351A/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152923A (en) * | 1989-06-26 | 1992-10-06 | Hans Georg Weder | Process for the production of a nanoemulsion of oil particles in an aqueous phase |
US6541018B1 (en) * | 1998-12-17 | 2003-04-01 | L'oreal | Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
US20020015721A1 (en) * | 1999-01-05 | 2002-02-07 | Jean-Thierry Simonnet | Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
US20070053988A1 (en) * | 2003-10-13 | 2007-03-08 | Audrey Royere | Monodispersed solid lipid particle compositions |
WO2006102768A1 (en) * | 2005-04-01 | 2006-10-05 | Alpharx Inc. | Colloidal solid lipid vehicle for pharmaceutical use |
US20060257493A1 (en) * | 2005-04-28 | 2006-11-16 | Amiji Mansoor M | Nanoparticulate delivery systems for treating multi-drug resistance |
Non-Patent Citations (2)
Title |
---|
Jiang et al. "ɤ-Tocopherol, the major form of vitamin E in the US diet, deserves more attention", Am J Clin Nutr 2001; 74: 714-22. * |
Weyenberg et al. "Cytotoxicity of submicron emulsions and solid lipid nanparticles for dermal application" ,International Journal of Pharmaceutics, 337 (2007) 291-298. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100303732A1 (en) * | 2007-09-14 | 2010-12-02 | Mivenion Gmbh | Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations |
US9821077B2 (en) | 2007-09-14 | 2017-11-21 | Nanopet Pharma Gmbh | Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations |
US20110200532A1 (en) * | 2008-08-14 | 2011-08-18 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Fluorescent emulsion of indocyanine green |
US20110274622A1 (en) * | 2008-08-14 | 2011-11-10 | Commissariat a L"energie atomique et aux energies alternatives | Nanocrystal Nano-Emulsion |
US9180210B2 (en) * | 2008-08-14 | 2015-11-10 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Nanocrystal nano-emulsion |
US9289517B2 (en) * | 2008-08-14 | 2016-03-22 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Fluorescent emulsion of indocyanine green |
US10092506B2 (en) | 2008-08-14 | 2018-10-09 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion |
US20130251629A1 (en) * | 2010-02-17 | 2013-09-26 | Commissariat a l'energie atomique et aux energies alternatives PARIS FRANCE Nationality: French | Nanoemulsion for the delivery of at least two agents of interest |
CN102166270A (en) * | 2011-04-06 | 2011-08-31 | 西北农林科技大学 | Oil-in-water type dried orange peel oil nano-emulsion and preparation method thereof |
WO2013008083A1 (en) * | 2011-07-13 | 2013-01-17 | National Institute Of Pharmaceutical Education And Research (Niper) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen |
US9707305B2 (en) | 2011-10-05 | 2017-07-18 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Formulas for diagnosing and treating hormone-dependent cancers and cancers of the organs responsible for steroid hormone synthesis |
CN104152138A (en) * | 2014-06-26 | 2014-11-19 | 苏州科技学院 | Weak light frequency upconversion o/w type microemulsion system |
Also Published As
Publication number | Publication date |
---|---|
US9072775B2 (en) | 2015-07-07 |
WO2008104717A3 (en) | 2009-02-19 |
EP2129455A2 (en) | 2009-12-09 |
IL200115A (en) | 2015-09-24 |
WO2008125747A3 (en) | 2009-03-19 |
EP2129455B1 (en) | 2014-04-23 |
WO2008102065A1 (en) | 2008-08-28 |
US20100284932A1 (en) | 2010-11-11 |
JP2010517768A (en) | 2010-05-27 |
JP2010518152A (en) | 2010-05-27 |
JP5620111B2 (en) | 2014-11-05 |
JP5837279B2 (en) | 2015-12-24 |
IL200115A0 (en) | 2010-04-15 |
WO2008104717A2 (en) | 2008-09-04 |
IL200351A (en) | 2016-02-29 |
EP2131869A2 (en) | 2009-12-16 |
WO2008125747A2 (en) | 2008-10-23 |
EP2131869B1 (en) | 2018-10-17 |
ES2482090T3 (en) | 2014-08-01 |
IL200351A0 (en) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100144899A1 (en) | Method for preparing nano-emulsions | |
US5660858A (en) | Cyclosporin emulsions | |
AU2009280803B2 (en) | Stable injectable oil-in-water Docetaxel nanoemulsion | |
CA2294337C (en) | Preparation of pharmaceutical compositions | |
US20020025337A1 (en) | Lipid vehicle drug delivery composition containing vitamin e | |
KR20010100194A (en) | Composition and formulation for solubilization of various compounds and preparation method thereof | |
JP2011505235A (en) | Nanoemulsion | |
KR101391020B1 (en) | Pharmaceutical composition containing hardly water soluble medicament | |
IE62194B1 (en) | Lipid formulation systems | |
WO2011101602A1 (en) | Nanoemulsion for the delivery of at least two agents of interest | |
EP1498143A1 (en) | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids | |
US20240009122A1 (en) | Small Molecule Formulation | |
WO2023054704A1 (en) | Method for producing complex dispersion in oil comprising water-soluble compound and lecithin | |
KR100778946B1 (en) | Nano?concentrated capsule compositions with high content oil?soluble active materials, it's manufacturing method and cosmetic composition containing the same | |
PL240303B1 (en) | Nanostructured lipid carriers stabilized with phosphatidylcholine and method of their preparation | |
PL240302B1 (en) | Solid lipid nanoparticles stablized with phosphatidylcholine and method of their preparation | |
PL240301B1 (en) | Nanostructured lipid carriers stabilized with phosphatidylcholine and method of their preparation | |
PL240300B1 (en) | Solid lipid nanoparticles stablized with phosphatidylcholine and method of their preparation | |
KR20050045831A (en) | Method for preparing phytosphingosine liposome composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE,FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOUTAYER, MATHIEU;TEXIER-NOGUES, ISABELLE;BIBETTE, JEROME;REEL/FRAME:024111/0454 Effective date: 20100223 |
|
AS | Assignment |
Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES Free format text: CHANGE OF NAME;ASSIGNOR:COMMISSARIAT A L'ENERGIE ATOMIQUE;REEL/FRAME:025673/0207 Effective date: 20100310 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |